BACKGROUND: Knowledge of antimicrobial resistance patterns in E. coli, the predominant pathogen associated with urinary tract infection (UTI) is important as a guide in selecting empirical antimicrobial therapy AIMS: To describe the antimicrobial susceptibility of E. coli associated with UTI in a region in the West of Ireland. METHODS: A collection of 934 E. coli isolates associated with UTI were tested for susceptibility to a panel of antimicrobial agents by the disc diffusion method of the National Committee for Clinical Laboratory Standards. RESULTS: More than 50% of E. coli were resistant to ampicillin, more than 40% resistant to sulphonamide and more than 30% resistant to trimethoprim. From 7.9% (community) to 12.5% (hospital) are resistant to co-amoxiclav with approximately 20% of isolates of intermediate susceptibility. In general practice most E. coli remain susceptible to nitrofurantoin (96.7%), nalidixic acid (93.9%) and ciprofloxacin (94.7%). For all agents rates of resistance were higher in hospital as compared with general practice isolates. Three isolates with the phenotype of Extended Spectrum Beta-lactamase (ESBL) resistance were detected. CONCLUSIONS: Ampicillin/amoxicillin are not suitable for empiric therapy of UTI in general practice or hospital patients in this region. There is doubt as to the role of trimethorpim or co-trimoxazole for empiric therapy of UTI. Nitrofurantoin, nalidixic acid and ciprofloxacin are active against the great majority of UTI associated E. coli.
BACKGROUND: Knowledge of antimicrobial resistance patterns in E. coli, the predominant pathogen associated with urinary tract infection (UTI) is important as a guide in selecting empirical antimicrobial therapy AIMS: To describe the antimicrobial susceptibility of E. coli associated with UTI in a region in the West of Ireland. METHODS: A collection of 934 E. coli isolates associated with UTI were tested for susceptibility to a panel of antimicrobial agents by the disc diffusion method of the National Committee for Clinical Laboratory Standards. RESULTS: More than 50% of E. coli were resistant to ampicillin, more than 40% resistant to sulphonamide and more than 30% resistant to trimethoprim. From 7.9% (community) to 12.5% (hospital) are resistant to co-amoxiclav with approximately 20% of isolates of intermediate susceptibility. In general practice most E. coli remain susceptible to nitrofurantoin (96.7%), nalidixic acid (93.9%) and ciprofloxacin (94.7%). For all agents rates of resistance were higher in hospital as compared with general practice isolates. Three isolates with the phenotype of Extended Spectrum Beta-lactamase (ESBL) resistance were detected. CONCLUSIONS:Ampicillin/amoxicillin are not suitable for empiric therapy of UTI in general practice or hospital patients in this region. There is doubt as to the role of trimethorpim or co-trimoxazole for empiric therapy of UTI. Nitrofurantoin, nalidixic acid and ciprofloxacin are active against the great majority of UTI associated E. coli.
Authors: Thomas M Hooton; Delia Scholes; Kalpana Gupta; Ann E Stapleton; Pacita L Roberts; Walter E Stamm Journal: JAMA Date: 2005-02-23 Impact factor: 56.272
Authors: I M Cullen; R P Manecksha; E McCullagh; S Ahmad; F O'Kelly; R Flynn; T E D McDermott; P Murphy; R Grainger; J P Fennell; J A Thornhill Journal: Ir J Med Sci Date: 2012-06-06 Impact factor: 1.568
Authors: Ján Koreň; Katarína Čurová; Marta Kmeťová; Leonard Siegfried; Viktor Jankó; László Kovács; Helena Hupková; Ján Luha Journal: Folia Microbiol (Praha) Date: 2012-06-21 Impact factor: 2.099
Authors: Daniela A López-Banda; Erika M Carrillo-Casas; Margarita Leyva-Leyva; Gabriel Orozco-Hoyuela; Ángel H Manjarrez-Hernández; Sara Arroyo-Escalante; David Moncada-Barrón; Silvia Villanueva-Recillas; Juan Xicohtencatl-Cortes; Rigoberto Hernández-Castro Journal: Biomed Res Int Date: 2014-05-05 Impact factor: 3.411